Sirona

SironaSirona
Sirona

Sirona

AI-native radiology workflow software that unifies diagnostic viewing, reporting, PACS, worklist, and AI into a single cloud-native platform.

Website
DR 02017Inactive41San Francisco, United States
Rate
Advertise here

About

Sirona Medical is a leader in AI-native radiology workflow software. The company's cloud-native platform, RadOS, is the industry's first unified radiology operating system, bringing together the diagnostic viewer, reporter, PACS archive, worklist, and AI into a single efficient clinical workflow. Sirona enables radiologists to work faster, deploy AI more effectively, and deliver better care for patients from anywhere. The company has raised over $110 million in venture capital and is trusted by large radiology practices, hospitals, and health systems globally.
Frequently asked

What does Sirona do?

Sirona Medical is a leader in AI-native radiology workflow software. The company's cloud-native platform, RadOS, is the industry's first unified radiology operating system, bringing together the diagnostic viewer, reporter, PACS archive, worklist, and AI into a single efficient clinical workflow. Sirona enables radiologists to work faster, deploy AI more effectively, and deliver better care for patients from anywhere. The company has raised over $110 million in venture capital and is trusted by…

What is Sirona's revenue?

StartupHub estimates Sirona's annual revenue at $14.9M (range $13.6M to $23.1M, 62% confidence), based on comparable companies in the sector.

Where is Sirona headquartered?

Sirona is headquartered in San Francisco, United States.

When was Sirona founded?

Sirona was founded in 2017.

What industry does Sirona operate in?

Sirona operates in Sports, Analytics, Sports Tech, HealthTech, AI-Driven Training, Personalized Fitness.

How many employees does Sirona have?

Sirona has approximately 41 people on record.

What is Sirona's current status?

Sirona's current operating status is: Inactive.

HEADCOUNT
41
DOMAIN RATING
0
Comments

No comments yet. Be the first to share your take.